antithymocyte globulin atg infusion horse rabbitderived antibodies human cells precursors thymocytes used prevention treatment acute rejection organ transplantation therapy aplastic anemia due bone marrow insufficiency two antithymocyte globulin atg agents licensed clinical use united states thymoglobulin rabbit atg ratg genzyme atgam equine atg eatg pfizer thymoglobulin atgam currently licensed use treatment renal allograft rejection atgam additionally licensed use treatment aplastic anemia drugs used offlabel applications especially immunosuppression induction agents andor kidney transplantation rabbit antit lymphocyte globulin made neovii pharmaceuticals marketed outside united states name grafalon atg administration substantially reduces immune competence patients normal immune systems combination actions explicitly understood hypothetical ratg particular effects large reductions cell lysis number circulating lymphocytes hence preventing least delaying cellular rejection transplanted organs however medical opinion remains divided benefit profound reduction cells outweighs concomitant increased risks infection malignancy united states frequently given time transplant prevent graftversushost although many european centers prefer reserve use treatment steroidresistant acute rejection european centres generally serve homogeneous populations rejection tends less problemcitation needed atg use induce cytokine release syndrome thought increase risk posttransplant lymphoproliferative disorder ptld however association may apply lower dosing regimens used evidence suggest inducing immunosuppression ratg organ transplantation may create conditions patients immune system favorable development immunological tolerance exact basis development remains largely speculative temporary depletion tcell population time transplant also risks delayed acute rejection may missed cause severe damage graft receptor antibodies basiliximab daclizumab increasingly used place atg induction therapy cause cytokine release syndrome theoretically improve development tolerance cytokine release syndrome associated atg administration frequently causes high grade fevers chills possibly rigors administration reason steroids normally methylprednisolone diphenhydramine mg acetaminophen mg usually coadministered adverse reactions often controlled slowing infusion rate first report immunizing animal one species guinea pig immune cells another species mouse lymphocytes Ã©lie metchnikoff reported injecting cells recovered mouse lymph nodes guinea pigs waiting immunization result accumulation antimouse antibodies guinea pig blood subsequently collected serum guinea pigs injected normal mice observed marked depletion number circulating mouse lymphocytes rabbit atg used two randomised trials reduce acute graft versus host disease recipients receiving progenitor cell higher doses mgkg reduced acute graft versus host offset increased infections however long term follow showed high low mgkg doses chronic graft versus host similar trial antilymphocyte globulin showed trend reduction acute graft versus host statistically significant reduction chronic graft versus canadian blood marrow transplant group currently conducting first randomised trial chronic graft versus host using even lower dose rabbit atg mgkg attempt confirm observations endpoint reduction proportion patients chronic graft versus host year immunosuppressants httpsenwikipediaorgwikiantithymocyteglobulin